Key terms

About CTLT

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CTLT news

Apr 12 1:41am ET Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS) Apr 05 3:50am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR) Mar 15 4:55am ET Piper Sandler healthcare/pharma analysts hold analyst/industry conference call Mar 12 5:00pm ET Piper Sandler healthcare/pharma analysts hold analyst/industry conference call Mar 07 1:49pm ET William Blair healthcare analysts hold analyst/industry conference call Mar 05 1:23am ET Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT) Feb 20 7:31am ET Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and Catalent (CTLT) Feb 15 1:00am ET A New Cause for Concern: Catalent Inc Adds a New Share Price & Shareholder Rights Risk Feb 12 5:24pm ET Catalent to delay 10-Q filing Feb 12 8:20am ET Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT) Feb 12 6:27am ET Catalent price target raised to $63.50 from $56 at Baird Feb 12 3:46am ET Catalent (CTLT) Gets a Hold from Barclays Feb 09 8:08am ET Catalent reports Q2 EPS (24c), consensus (2c) Feb 09 7:05am ET Options Volatility and Implied Earnings Moves Today, February 09, 2024 Feb 07 8:35am ET Analyst Maintains Hold Rating Amid Catalent’s Strategic Acquisition and Complex Valuation Feb 06 7:45am ET Novo Nordisk price target raised to $135 from $115 at TD Cowen Feb 06 5:06am ET Catalent downgraded to Sector Perform from Outperform at RBC Capital Feb 06 4:12am ET Catalent Announces Strategic Merger Agreement with Novo Holdings Feb 06 4:12am ET Catalent Finalizes Strategic Merger with Creek Parent, Inc. Feb 06 1:51am ET SPY ETF Update, 2/6/2024 Feb 06 1:25am ET Barclays Sticks to Their Hold Rating for Catalent (CTLT) Feb 05 8:29pm ET Catalent downgraded to Neutral from Buy at UBS Feb 05 6:29pm ET Catalent downgraded to Equal Weight from Overweight at Stephens Feb 05 12:00pm ET Catalent rises 9.6% Feb 05 10:00am ET Catalent rises 9.8% Feb 05 9:55am ET Early notable gainers among liquid option names on February 5th Feb 05 9:47am ET Catalent rises 9.2% Feb 05 7:24am ET Novo Nordisk’s $16.5B Catalent (NYSE:CTLT) Deal, Shares Surge Feb 05 6:26am ET Catalent jumps 13% to $61.46 after Novo Holdings merger agreement Feb 05 6:11am ET Novo Holdings to sell three Catalent fill-finish sites after merger Feb 05 6:03am ET Novo Holdings to acquire Catalent for $63.50 per share in cash, or $16.5B

No recent press releases are available for CTLT

CTLT Financials

1-year income & revenue

Key terms

CTLT Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CTLT Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms